SCHEMBL4393219

SCHEMBL4393219

[CH2]c1cccc(Oc2cccc(C(C)=O)c2C(C)=O)c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.39
THRB P10828 1/20 0.38
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.34
MAOB P27338 2/20 0.33
MAPK1 P28482 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
KLKB1 P03952 1/20 0.33
ESR1 P03372 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33
HMGB1 P09429 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7613367 0.85 KMT2A (0.49) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL4398297 0.83 KDM4E (0.46) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL1574451 0.76 THRB (0.41) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL1683823 0.76 THRB (0.46) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL6857330 0.74 CTNNB1 (0.54) KMT2ALMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL2986261 0.73 CA9 (0.59) KMT2ALMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL9639967 0.73 KDM4E (0.43) KMT2ALMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL8443029 0.72 KMT2A (0.46) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL10831160 0.70 KMT2A (0.45) KMT2ATHRBLMNASMN1; SMN2KDM4E
SCHEMBL29080260 0.70 KMT2A (0.49) KMT2ATHRBLMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572907-B2 Methods and compounds for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2009-08-11 US disclosed
EP-1717242-A1 Polynucleotide synthesis Agilent Technologies, Inc. (US) 2006-11-02 EP disclosed
US-20060247430-A1 Methods and compounds for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247430-A1 Methods and compounds for polynucleotide synthesis POLN, POLRMT, POLM KMT2A 3846/4885THRB 3315/4885LMNA 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.